UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
December 6, 2012
ASTEX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
0-27628 |
|
91-1841574 |
|
(State or other jurisdiction of |
|
(Commission File Number) |
|
(IRS Employer |
4140 Dublin Blvd., Suite 200
Dublin, CA 94568
(Address of principal executive offices, including zip code)
(925) 560-0100
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Bonuses for Executive Officers
On December 6, 2012, the Astex Pharmaceuticals Compensation Committee approved cash bonus awards to the executive officers of the company for their performance in calendar year 2012. The approved cash bonuses are as follows:
|
Name and Position |
|
Bonus |
|
|
James S.J. Manuso, PhD |
|
$575,000 |
|
|
Chief Executive Officer |
|
|
|
|
Harren Jhoti, PhD (1) |
|
£152,903 |
|
|
President |
|
|
|
|
Mohammad Azab, MD |
|
$248,000 |
|
|
Chief Medical Officer |
|
|
|
|
Martin Buckland, DPhil (1) |
|
£85,806 |
|
|
Chief Business Officer |
|
|
|
|
Michael Molkentin |
|
$198,000 |
|
|
Chief Financial Officer |
|
|
|
(1) To be paid in British Pounds Sterling.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
ASTEX PHARMACEUTICALS, INC. |
|
|
|
|
|
|
By: |
/s/ MICHAEL MOLKENTIN |
|
|
|
Michael Molkentin Chief Financial Officer |
Date: December 12, 2012